Evidence map›Paper›PMID 29753204›Full record

ReviewCurrent opinion in structural biology2018

Next-generation antibodies for post-translational modifications.

Takamitsu Hattori, Shohei Koide

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in structural biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Article
  3. Exploring Biophysics at the Membrane with Single-Molecule TIRF Microscopy.Advances in experimental medicine and biology · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Takamitsu HattoriPerlmutter Cancer Center, New York University Langone Medical Center, New York, NY 10016, United States; Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, United States. Electronic address: Takamitsu.Hattori@nyumc.org.
Shohei KoidePerlmutter Cancer Center, New York University Langone Medical Center, New York, NY 10016, United States; Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, United States; Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago, IL 60637, United States. Electronic address: Shohei.Koide@nyumc.org.
NYU Langone Health · USUniversity of Chicago · US

Funding

Genetically encoded designer inhibitors for functional epigenomicsR01DA036887 · NIDA · UNIVERSITY OF CHICAGO · PI KOIDE, SHOHEI · 2013 to 2017
$2.0M
Molecular mechanisms of SHP2 signaling dissected with designer binding proteinsR01CA194864 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KOIDE, SHOHEI · 2016 to 2020
$1.8M
NCI NIH HHS R01 CA194864NIDA NIH HHS R01 DA036887
6 · The paper itself

Abstract

Despite increasing demands for antibodies to post-translational modifications (PTMs), fundamental difficulties in molecular recognition of PTMs hinder the generation of highly functional anti-PTM antibodies using conventional methods. Recently, advanced approaches in protein engineering and design that have been established for biologics development were applied to successfully generating highly functional anti-PTM antibodies. Furthermore, structural analyses of anti-PTM antibodies revealed unprecedented binding modes that substantially increased the antigen-binding surface. These features deepen the understanding of mechanisms underlying specific recognition of PTMs, which may lead to more effective approaches for generating anti-PTM antibodies with exquisite specificity and high affinity.

Indexed as

Protein EngineeringAntibodiesDrug DesignModels, MolecularProtein BindingProtein ConformationProtein Processing, Post-TranslationalStructure-Activity RelationshipAntibodies

Identifiers

PMID29753204
PMCPMC6686900
OpenAlexW2799634000

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.